Brief: Celyad Oncology To Present Updates On shRNA-Based CAR T Programs

Celyad Oncology SA

13/12/2021 06:06

Dec 13 (Reuters) - Celyad Oncology SA  CYAD.BR :
    * CELYAD ONCOLOGY PRESENTS UPDATES ON SHRNA-BASED CAR T
PROGRAMS
AT 63RD ASH ANNUAL MEETING AND EXPOSITION
    * DATA CONTINUES TO SUPPORT VERSATILE POTENTIAL OF NON-GENE
EDITED
SHRNA TECHNOLOGY WITH UPDATES FROM CYAD-02 AND CYAD-211 CLINICAL
PROGRAMS
    * DATA FROM AUTOLOGOUS NKG2D RECEPTOR CAR T CANDIDATE
CYAD-02
USING SHRNA SHOWS A SINGLE SHRNA CAN TARGET TWO INDEPENDENT
GENES TO ENHANCE PHENOTYPE OF CAR T CELLS
    * FAVORABLE TOLERABILITY PROFILE FOR CYAD-02 WITH A LOW RATE
OF
GRADE ≥ 3 CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED OR
REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME
(R/R AML / MDS)
    * ENROLLMENT IN COHORTS EVALUATING ENHANCED LYMPHODEPLETION
IS
ONGOING. ADDITIONAL DATA FROM CYAD-211 IMMUNICY-1 TRIAL ARE
EXPECTED IN MID-2022
    * MANAGEMENT TO HOST CONFERENCE CALL TODAY DECEMBER 13TH AT
2:30
P.M. CET / 8:30 A.M. EST

Source text for Eikon:  ID:nGNX77NXZ0 
Further company coverage:  CYAD.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))